Access cutting-edge follicular lymphoma treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access follicular lymphoma specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related follicular lymphoma treatment provided free
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving r
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this follicular lymphoma clinical trial in Birmingham, AL
If you're searching for follicular lymphoma treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced follicular lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.